In:
Clinical and Experimental Pediatrics, Korean Pediatric Society, Vol. 64, No. 12 ( 2021-12-15), p. 602-607
Abstract:
In April 2020, the Ministry of Food and Drug Safety licensed a hexavalent combined diphtheria and tetanus toxoids and acellular pertussis (DTaP), inactivated poliovirus (IPV), Haemophilus influenzae type b (Hib) conjugated to tetanus protein, and hepatitis B (HepB) (recombinant DNA) vaccine, DTa-PIPV-Hib-HepB (Hexaxim, Sanofi Pasteur), for use as a 3-dose primary series in infants aged 2, 4, and 6 months. The DTaP-IPVHib-HepB vaccine is highly immunogenic and safe and provides a long-term immune response based on studies performed in a variety of settings in many countries, including Korea. This report summarizes the Committee on Infectious Diseases of the Korean Pediatric Society guidelines for the use of this newly introduced hexavalent combination vaccine.
Type of Medium:
Online Resource
ISSN:
2713-4148
DOI:
10.3345/cep.2021.00507
Language:
English
Publisher:
Korean Pediatric Society
Publication Date:
2021
detail.hit.zdb_id:
2594966-4
Permalink